Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia

Chin Cheng Lee, Che P. Lin, Yueh L. Lee, Giueng Chueng Wang, Yuan Chih Cheng, H. Eugene Liu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Meisoindigo, a derivative of Indigo naturalis, has been used in China for chronic myeloid leukemia. In vitro cell line studies have shown that this agent might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML). In this study, we explored its mechanisms and potential in AML. NB4, HL-60, and U937 cells and primary AML cells were used to examine its effects and the NOD/SCID animal model was used to evaluate its invivo activity. Meisoindigo inhibited the growth of leukemic cells by inducing marked apoptosis and moderate cell-cycle arrest at the G0/G1 phase. It down-regulated anti-apoptotic Bcl-2, and up-regulated pro-apoptotic Bak and Bax and cell-cycle related proteins, p21and p27. Furthermore, it induced myeloid differentiation, as demonstrated by morphologic changes, up-regulation of CD11b, and increased nitroblue tetrazolium reduction activity in all cell lines tested. In addition, meisoindigo down-regulated the expression of human telomerase reverse transcriptase and enhanced the cytotoxicity of conventional chemotherapeutic agents, cytarabine and idarubicin. As with the results from cell lines, meisoindigo also induced apoptosis, up-regulated p21 and p27, and down-regulated Bcl-2 in primary AML cells. The invivo anti-leukemic activity of meisoindigo was also demonstrated by decreased spleen size in a dose-dependent manner. Taking these results together, meisoindigo is a potential agent for AML.

Original languageEnglish
Pages (from-to)897-905
Number of pages9
JournalLeukemia and Lymphoma
Volume51
Issue number5
DOIs
Publication statusPublished - May 2010

Fingerprint

Acute Myeloid Leukemia
Human Activities
Myeloid Cells
Apoptosis
Cell Line
Indigo Carmine
Idarubicin
Nitroblue Tetrazolium
Cell Cycle Resting Phase
Cell Cycle Proteins
U937 Cells
HL-60 Cells
Cytarabine
G1 Phase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell Cycle Checkpoints
N-methylisoindigotin
In Vitro Techniques
China
Up-Regulation

Keywords

  • Acute myeloid leukemia
  • Apoptosis
  • Meisoindigo

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. / Lee, Chin Cheng; Lin, Che P.; Lee, Yueh L.; Wang, Giueng Chueng; Cheng, Yuan Chih; Liu, H. Eugene.

In: Leukemia and Lymphoma, Vol. 51, No. 5, 05.2010, p. 897-905.

Research output: Contribution to journalArticle

Lee, Chin Cheng ; Lin, Che P. ; Lee, Yueh L. ; Wang, Giueng Chueng ; Cheng, Yuan Chih ; Liu, H. Eugene. / Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 5. pp. 897-905.
@article{74825ef3beb4414cb59de24478d4f0ed,
title = "Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia",
abstract = "Meisoindigo, a derivative of Indigo naturalis, has been used in China for chronic myeloid leukemia. In vitro cell line studies have shown that this agent might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML). In this study, we explored its mechanisms and potential in AML. NB4, HL-60, and U937 cells and primary AML cells were used to examine its effects and the NOD/SCID animal model was used to evaluate its invivo activity. Meisoindigo inhibited the growth of leukemic cells by inducing marked apoptosis and moderate cell-cycle arrest at the G0/G1 phase. It down-regulated anti-apoptotic Bcl-2, and up-regulated pro-apoptotic Bak and Bax and cell-cycle related proteins, p21and p27. Furthermore, it induced myeloid differentiation, as demonstrated by morphologic changes, up-regulation of CD11b, and increased nitroblue tetrazolium reduction activity in all cell lines tested. In addition, meisoindigo down-regulated the expression of human telomerase reverse transcriptase and enhanced the cytotoxicity of conventional chemotherapeutic agents, cytarabine and idarubicin. As with the results from cell lines, meisoindigo also induced apoptosis, up-regulated p21 and p27, and down-regulated Bcl-2 in primary AML cells. The invivo anti-leukemic activity of meisoindigo was also demonstrated by decreased spleen size in a dose-dependent manner. Taking these results together, meisoindigo is a potential agent for AML.",
keywords = "Acute myeloid leukemia, Apoptosis, Meisoindigo",
author = "Lee, {Chin Cheng} and Lin, {Che P.} and Lee, {Yueh L.} and Wang, {Giueng Chueng} and Cheng, {Yuan Chih} and Liu, {H. Eugene}",
year = "2010",
month = "5",
doi = "10.3109/10428191003672115",
language = "English",
volume = "51",
pages = "897--905",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia

AU - Lee, Chin Cheng

AU - Lin, Che P.

AU - Lee, Yueh L.

AU - Wang, Giueng Chueng

AU - Cheng, Yuan Chih

AU - Liu, H. Eugene

PY - 2010/5

Y1 - 2010/5

N2 - Meisoindigo, a derivative of Indigo naturalis, has been used in China for chronic myeloid leukemia. In vitro cell line studies have shown that this agent might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML). In this study, we explored its mechanisms and potential in AML. NB4, HL-60, and U937 cells and primary AML cells were used to examine its effects and the NOD/SCID animal model was used to evaluate its invivo activity. Meisoindigo inhibited the growth of leukemic cells by inducing marked apoptosis and moderate cell-cycle arrest at the G0/G1 phase. It down-regulated anti-apoptotic Bcl-2, and up-regulated pro-apoptotic Bak and Bax and cell-cycle related proteins, p21and p27. Furthermore, it induced myeloid differentiation, as demonstrated by morphologic changes, up-regulation of CD11b, and increased nitroblue tetrazolium reduction activity in all cell lines tested. In addition, meisoindigo down-regulated the expression of human telomerase reverse transcriptase and enhanced the cytotoxicity of conventional chemotherapeutic agents, cytarabine and idarubicin. As with the results from cell lines, meisoindigo also induced apoptosis, up-regulated p21 and p27, and down-regulated Bcl-2 in primary AML cells. The invivo anti-leukemic activity of meisoindigo was also demonstrated by decreased spleen size in a dose-dependent manner. Taking these results together, meisoindigo is a potential agent for AML.

AB - Meisoindigo, a derivative of Indigo naturalis, has been used in China for chronic myeloid leukemia. In vitro cell line studies have shown that this agent might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML). In this study, we explored its mechanisms and potential in AML. NB4, HL-60, and U937 cells and primary AML cells were used to examine its effects and the NOD/SCID animal model was used to evaluate its invivo activity. Meisoindigo inhibited the growth of leukemic cells by inducing marked apoptosis and moderate cell-cycle arrest at the G0/G1 phase. It down-regulated anti-apoptotic Bcl-2, and up-regulated pro-apoptotic Bak and Bax and cell-cycle related proteins, p21and p27. Furthermore, it induced myeloid differentiation, as demonstrated by morphologic changes, up-regulation of CD11b, and increased nitroblue tetrazolium reduction activity in all cell lines tested. In addition, meisoindigo down-regulated the expression of human telomerase reverse transcriptase and enhanced the cytotoxicity of conventional chemotherapeutic agents, cytarabine and idarubicin. As with the results from cell lines, meisoindigo also induced apoptosis, up-regulated p21 and p27, and down-regulated Bcl-2 in primary AML cells. The invivo anti-leukemic activity of meisoindigo was also demonstrated by decreased spleen size in a dose-dependent manner. Taking these results together, meisoindigo is a potential agent for AML.

KW - Acute myeloid leukemia

KW - Apoptosis

KW - Meisoindigo

UR - http://www.scopus.com/inward/record.url?scp=77951824361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951824361&partnerID=8YFLogxK

U2 - 10.3109/10428191003672115

DO - 10.3109/10428191003672115

M3 - Article

C2 - 20233051

AN - SCOPUS:77951824361

VL - 51

SP - 897

EP - 905

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -